SCHEMBL146252 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	PDE4A	P27815	4/20	0.46

▸	PDE4B	Q07343	4/20	0.46

▸	PDE4C	Q08493	4/20	0.46

▸	PDE4D	Q08499	4/20	0.46

▸	SMN1; SMN2	Q16637	2/20	0.46

▸	MAPT	P10636	1/20	0.46

▸	HTT	P42858	1/20	0.46

▸	TSHR	P16473	1/20	0.45

▸	LMNA	P02545	1/20	0.45

▸	NPC1	O15118	1/20	0.44

▸	TP53	P04637	1/20	0.44

▸	RAB9A	P51151	1/20	0.44

▸	ACKR3	P25106	2/20	0.43

▸	AAK1	Q2M2I8	3/20	0.43

▸	ALDH1A1	P00352	2/20	0.43

▸	GAA	P10253	1/20	0.43

▸	SIRT2	Q8IXJ6	1/20	0.42

▸	SIRT1	Q96EB6	1/20	0.42

▸	SIRT3	Q9NTG7	1/20	0.42

▸	MAPK1	P28482	1/20	0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL146508	0.92	PDE4A (0.48)	PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL139804	0.92	NPC1 (0.46)	PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL6684488	0.92	PDE4D (0.45)	PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL6653521	0.89	ACKR3 (0.44)	PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL6656438	0.88	PDE4D (0.44)	PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL148509	0.88	ABCB1 (0.44)	PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL144775	0.88	SMN1; SMN2 (0.44)	PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL144599	0.87	ABCB1 (0.44)	PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL142720	0.87	ABCG2 (0.52)	PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL6657995	0.87	PDE4D (0.43)	PDE4APDE4BPDE4CPDE4DMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20050070529-A1	Use of type 4 phosphodiesterase inhibitors in myocardial diseases	MERK PANTENT GMBH (DE)	2005-03-31	—	—	US	claimed
US-20040259863-A1	Type 4 phosphodiesterase inhibitors and uses thereof	MERCK PATENT GMBH (DE)	2004-12-23	—	—	US	claimed
EP-1463509-A1	TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF	MERCK PATENT GmbH (DE)	2004-10-06	—	—	EP	claimed
EP-1368035-A1	USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES	MERCK PATENT GmbH (DE)	2003-12-10	—	—	EP	claimed
WO-2003037349-A1	TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF	MERCK PATENT GMBH (DE)	2003-05-08	—	—	WO	claimed
WO-2002072103-A1	USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES	MERCK PATENT GMBH (DE)	2002-09-19	—	—	WO	claimed
US-20140221455-A1	DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR	Verva Pharmaceuticals, Inc. (AU)	2014-08-07	—	—	US	disclosed
US-20120059047-A1	DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR	VERVA PHARMACEUTICALS PTY LTD (AU)	2012-03-08	—	—	US	disclosed
US-20050282733-A1	Differentiation modulating agents and uses therefor	VERVA PHARMACEUTICALS PTY LTD (AU)	2005-12-22	—	—	US	disclosed
US-20050070529-A1	Use of type 4 phosphodiesterase inhibitors in myocardial diseases	MERK PANTENT GMBH (DE)	2005-03-31	—	—	US	disclosed
US-20040259863-A1	Type 4 phosphodiesterase inhibitors and uses thereof	MERCK PATENT GMBH (DE)	2004-12-23	—	—	US	disclosed
US-20040235845-A1	Use of phosphodiesterase iv inhibitors	MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE)	2004-11-25	—	—	US	disclosed
EP-1463509-A1	TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF	MERCK PATENT GmbH (DE)	2004-10-06	—	—	EP	disclosed
EP-1368035-A1	USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES	MERCK PATENT GmbH (DE)	2003-12-10	—	—	EP	disclosed
WO-2003037349-A1	TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF	MERCK PATENT GMBH (DE)	2003-05-08	—	—	WO	disclosed
WO-2003032993-A1	USE OF PHOSPHORODIESTERASE IV INHIBITORS	MERCK PATENT GMBH (DE)	2003-04-24	—	—	WO	disclosed
EP-0763534-B1	Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors	MERCK PATENT GMBH (DE)	2003-02-26	—	—	EP	disclosed
WO-2002072103-A1	USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES	MERCK PATENT GMBH (DE)	2002-09-19	—	—	WO	disclosed
US-5859008-A	Arylalkyl diazinones	MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE)	1999-01-12	—	—	US	disclosed
EP-0763534-A1	Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors	MERCK PATENT GmbH (DE)	1997-03-19	—	—	EP	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20120059047-A1	DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR	FGF1, FABP4, FGF2	PDE4A 1401/4885PDE4B 1040/4885PDE4C 1797/4885
US-20040235845-A1	Use of phosphodiesterase iv inhibitors	PDE4A, PDE3A, PDE3B	PDE4A 1/4885PDE4B 4/4885PDE4C 5/4885
US-20050282733-A1	Differentiation modulating agents and uses therefor	FGF1, FABP4, FGF2	PDE4A 1401/4885PDE4B 1040/4885PDE4C 1797/4885
US-20050070529-A1	Use of type 4 phosphodiesterase inhibitors in myocardial diseases	PDE4A, PDE4B, PDE12	PDE4A 1/4885PDE4B 2/4885PDE4C 5/4885
US-20040259863-A1	Type 4 phosphodiesterase inhibitors and uses thereof	PDE4A, PDE4B, PDE4C	PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.